Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome

INTRODUCTION: Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening form of thrombotic microangiopathy (TMA) which is caused by dysregulation of the alternative complement pathway (AP). Complement inhibition is an effective therapeutic strategy in aHUS, though curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanagh, David, Greenbaum, Larry A., Bagga, Arvind, Karki, Rajeshri G., Chen, Chien-Wei, Vasudevan, Sajita, Charney, Alan, Dahlke, Marion, Fakhouri, Fadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334406/
https://www.ncbi.nlm.nih.gov/pubmed/37441479
http://dx.doi.org/10.1016/j.ekir.2023.04.029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334406/
https://www.ncbi.nlm.nih.gov/pubmed/37441479
http://dx.doi.org/10.1016/j.ekir.2023.04.029

Ejemplares similares